Novo Nordisk A/S (Novo Nordisk A/S) Interest Expense

: $-205 Mil (TTM As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Novo Nordisk A/S's interest expense for the three months ended in Dec. 2023 was $ 307 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-205 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Novo Nordisk A/S's Operating Income for the three months ended in Dec. 2023 was $ 3,916 Mil. Novo Nordisk A/S's Interest Expense for the three months ended in Dec. 2023 was $ 307 Mil. Novo Nordisk A/S did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Novo Nordisk A/S Interest Expense Historical Data

The historical data trend for Novo Nordisk A/S's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-32.72

-63.77

-43.91

-53.82

-79.30

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense																1,144.40	-161.39	-40.89	-310.26	307.40

Novo Nordisk A/S Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-205 Mil.

Novo Nordisk A/S (NYSE:NVO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Novo Nordisk A/S's Interest Expense for the three months ended in Dec. 2023 was $307 Mil. Its Operating Income for the three months ended in Dec. 2023 was $3,916 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $3,003 Mil.

Novo Nordisk A/S's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

The higher the ratio, the stronger the company's financial strength is.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.